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Summary
Objective: A narrative review describing the assessment of osteoarthritis (OA) progression, and more speciﬁcally the risk factors which assist
in delineating strata of individuals at greatest risk for more rapid progression.
Design: A narrative review based on selected recent medical literature.
Results: With little currently available in the treatment of this disease, better understanding of responsive and valid endpoints is essential to
identifying potential new interventions for treatment of OA. Efforts to stratify those at greatest risk for progression can use a number of sys-
temic or local risk factors that may assist in delineating populations at greater risk for progression.
Conclusions: Current data suggests that stratiﬁcation of risk is feasible to ascertain those at risk for rapid progression using a number of dif-
ferent metrics including knee alignment, meniscal damage, bone marrow lesions and late stage disease. Identifying persons at greatest risk for
progression has important implications for clinical trial planning and can enhance study efﬁciency.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The paper is a narrative review of selected recent literature
of some methods of stratiﬁcation of knee osteoarthritis (OA)
progression.
One proposed OA treatment goal is modiﬁcation of the un-
derlying joint structure. This treatment goal has becomeama-
jor focus of drug development in OA. Some studies with
varying levels of evidence suggest that glucosamine sulfate,
chondroitin sulfate, sodium hyaluronan, doxycycline, matrix
metalloproteinase (MMP) inhibitors, bisphosphonates, calci-
tonin, diacerein and avocado-soybean unsaponiﬁables may
modify disease progression1. However, further deﬁnitive
structure modifying therapeutic development is constrained
by the need for long-term follow-up to observe changes in
structure (and potential drug effects on it). Therefore, accu-
rate, highly reproducible and responsive measures of the
rate of disease progression are a prerequisite for assessing
structural change in clinical trials.
Traditionally measurement of OA structural change has
been performed using radiographs2. Due to inherent limita-
tions in plain radiograph technology, further research and de-
velopment has investigated other techniques that may
improve the assessment of disease, its early development
and its progression. Foremost among these is Magnetic Res-
onance Imaging (MRI), a non-invasive three dimensional (3D)
method for assessing joint morphology that may supplant the*Address correspondence and reprint requests to: David J. Hunter,
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1402widespreaduseofplain radiographs inclinical trials3.However
whilst MRI has enormous potential, recent studies provide
a note of caution for its immediate ability to supersede the
weight-bearing radiograph. The responsiveness of different
measures of cartilage morphometry may not be as great as
early data suggested4e6. Conservative study designs based
on largeMRI progression series currently in the public domain
require large sample sizes, if quantitative cartilage morphom-
etry measures are used as the endpoint. If one could conﬁ-
dently design studies based on smaller sample sizes and/or
shorter study durations, this would, greatly reduce the re-
source implications for MRI-based interventional studies.
Several studies have suggested that baseline clinical,
biomarker and imaging features are predictive of progres-
sion of cartilage loss in the medial compartment of the
knee and could be used to provide greater study power
by selecting a population at greater risk for more rapid
progression.
This narrative review will be broadly divided into three
major areas. Firstly the methods of assessment of OA pro-
gression will be brieﬂy discussed. For further detail on this
please see other recent reviews2,4,7. Following this, exam-
ples of the risk factors which assist in delineating strata of
individuals at greatest risk for more rapid progression will
be appraised. Ultimately, the use of these strata can impact
clinical trial efﬁciency and the implications of the use of
these risk factors on trial design will also be considered.
Methods
The paper is a narrative review of methods of stratiﬁcation of knee OA
progression. The included studies were identiﬁed through manual and elec-
tronic searches. The manual searches included scanning of bibliographies,
journals, and conference proceedings and correspondence with experts.
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1403Osteoarthritis and Cartilage Vol. 17, No. 11The electronic searches were performed in the Cochrane Database of Sys-
tematic Reviews, ACP Journal Club, Database of Reviews of Effects and
MEDLINE. No limitations were used for year of publication or language.
The keywords used in the electronic searches included ‘‘knee OA,’’ ‘‘progres-
sion,’’ and ‘‘stratiﬁcation’’. The searches were completed on February 12,
2009. Like all narrative reviews this is not a systematic approach to obtain
primary data, or to integrate ﬁndings, or to test hypotheses. Interpretation
is dependent on the opinion of the reviewer. In addition there is no use of ex-
plicit standards to evaluate the quality of the studies under review and no at-
tempt is made to synthesize the data quantitatively. For readers interested in
a systematic review of prognostic factors for knee OA progression please
see the recent review by Belo et al 8.-8
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Fig. 1. Longitudinal change of knee cartilage volume with MRI from
different studies4,5,27e33.Plain radiography
Traditionally the progression of knee OA has been assessed by measur-
ing changes in the width of the space between the medial femoral condyle
and medial tibial plateau on plain X-rays using standardized radiographic
protocols of the ﬂexed knee9. A reduction in cartilage thickness is inferred
from a reduction in this space9,10.
Recent analyses suggest that the better the positioning in terms of medial
tibial rim alignment (or interim distance) with the X-ray beam, the greater is
the sensitivity to detect OA progression and the more accurate identiﬁcation
of the location of joint space narrowing (JSN)11e13.
A number of different radiographic protocols of the knee in ﬂexion have
been developed and shown to improve the detection of JSN by providing
a better exposure of the location of the greater cartilage changes in the pos-
terior area of the femoral condyles14. There remains however considerable
controversy over the preferred method of knee radiographic acquisition9,15,16
and joint space width (JSW) measurement10,17e20. The smallest standard
deviation (SD) of the difference between testeretest measurements of min-
imum JSW in pairs of radiographs reaches about 0.1 mm in the most repro-
ducible methods20,21 indicating a smallest detectable difference (SDD) of at
least 0.2 mm, which remains relatively large considering the 0.10e0.15 mm
expected average annual JSN of OA knee joints.
MRI
Broadly speaking, MRIs of OA structure can be measured semi-quantita-
tively or quantitatively, and either morphological or compositional measure-
ments of articular cartilage can be obtained.
Semi-quantitative scoring of MRIs is a valuable method for performing
multi-feature assessment of the knee using conventional MRI acquisi-
tions22e25. Such approaches score, in an observer-dependent semi-quantita-
tive manner, a variety of features that are currently believed to be relevant to
the functional integrity of the knee. The observed sensitivity to change has
been relatively small6. At the present time, the limited longitudinal data on
these scoring systems compared to quantitative morphological cartilage
measurement somewhat precludes their use as primary outcome. However,
recent data suggests that full thickness defects may occur as part of early
disease and that quantitative morphometry appears most useful (sensitive
to change) in persons with late stage disease (in those with established
JSN)26.
The 3D coverage of an entire cartilaginous region by MRI allows for the
direct quantiﬁcation of cartilage volume, surface areas and thickness4. Early
longitudinal studies demonstrated changes of cartilage volume on the order
of 4% to 6% (SD ofw5%) occur per annum in OA in most knee compart-
ments followed for periods up to 3 years4. More recent studies, however, ob-
served smaller rates of change than those quoted above with rates of about
1% to 3% and standardized response means (SRM) of 0.3 to 0.5 per
year5,27e29 (see Fig. 1 delineating greater change in examples of earlier
studies than examples of more recent analyses).RISK FACTORS FOR OA PROGRESSIONDue to limitations in the responsiveness of both radiographic and MRI
measures of progression, efforts are being made to stratify those who are
at highest risk of progression. Several studies have suggested that baseline
clinical, biomarker and imaging features are predictive of progression of car-
tilage loss in the medial compartment of the knee and could be used to pro-
vide greater study power by selecting a population at greater risk for more
rapid progression.
Broadly these risk/prognostic factors can be characterized into systemic
(age, gender, bone density, etc.) vs local factors (malalignment, meniscal
damage, etc.).
Of the systemic factors, increasing age34,35, female gender34e36, low
systemic bone density37,38, higher insulin-like growth factor-1 (IGF-1)39,
higher c-reactive protein (CRP)40, non-smoking status41, and never using
estrogen compared to current estrogen use42 have all been associatedwith a mildly increased risk for knee OA progression8. The presence of
generalized or nodal OA35,36,43,44, low Vitamin D45 and obesity34,35,43,46,47
have also been associated with a more pronounced increased risk of knee
OA progression8. It is important to note that the results of the inﬂuence of
Vitamin D deﬁciency on the risk of progression are conﬂicting45,48. Simi-
larly the inﬂuence of obesity on progression (unlike its unquestionably im-
portant effects on OA incidence) is also conﬂicting and much of this effect
appears to be mediated by alignment49.
Biochemical markers are typically systemic measures of local pathology.
The ability to use biochemical markers to predict disease progression and
identify patients most likely to progress may accelerate the pace of therapeu-
tic development. Research on type II collagen has suggested that assays for
type II collagen degradation when used in combination or with markers of
collagen synthesis can distinguish populations with knee OA that exhibit pro-
gression of joint damage from non-progressors. The ratio of the type II colla-
gen crosslinking C-telopeptide (CTX-II) to the amino-propeptide of type IIA
collagen50 or the ratio of two collagenase-generated cleavage epitopes in
the helical region (C1, 2C to C2C)51 can each make this distinction. Prelim-
inary plain radiographic studies suggest that COMP may be a useful prog-
nostic marker of disease progression in knee52e54 and hip OA55. In
addition serum measurement of hyaluronic acid and keratan sulfate may
be helpful prognostic predictors of persons at risk for knee OA progres-
sion56,57. The data is conﬂicting and not all studies show that biomarkers
can predict progression58,59.
When stratifying risk it is important that the effects of risk factors are
broadly consistent across studies, they are preferably potent risk factors
and that the effect does not produce substantial potential for misclassiﬁca-
tion. In this light, the local factors discussed below show great promise. Local
factors include the presence of varus malalignment at the tibiofemoral (TF)
joint27,60 and the presence on MRI of subchondral bone marrow lesions
(BML)61 or meniscal abnormalities62. The presence of knee pain has also
been associated inconsistently with an increased risk for knee OA progres-
sion34,43,63. What follows is a more extensive description of these local
factors.
Alignment
Mechanical factors are the dominant risk factor for structural progression.
Varus and valgus malalignment have been shown to increase the risk of sub-
sequent medial and lateral knee OA radiographic progression, respec-
tively60. Varus malalignment has been shown to lead to a 4-fold
ampliﬁcation of focal medial knee OA progression while valgus malalignment
has been shown to predispose to a 2- to 5-fold increase in lateral OA pro-
gression60,64. In an MRI-based study, varus malalignment predicted medial
tibial cartilage volume and thickness loss, and tibial and femoral denuded
bone increase, after adjusting for other local factors (meniscal damage
and extrusion, laxity)27. Understanding the role alignment plays in OA pro-
gression is important because it modulates the effect of standard risk factors
for knee OA progression including obesity49, quadriceps strength65, laxity65
and stage of disease60,64. Acquisition of the radiographs for alignment mea-
surement, and their processing, are relatively inexpensive and readily
available.
Malalignment however, provides only a static impression of the mechan-
ical forces being imparted on a joint in one plane66. The adduction moment at
the knee has been related to the progression of medial compartment OA67,68.
Application of screening methods for
detecting persons at risk for rapid progression
• Inexpensive
• Minimally burdensome
• Readily available at multiple centers
• High positive predictive value for
  detecting rapid progression.
• Low screen failure rate
1404 D. J. Hunter: Risk stratiﬁcation for knee OA progressionThe number of gait laboratories that are suitable for acquiring data on the ad-
duction moment, and the time and expense to acquire and process this data,
make this risk factor less suitable for stratifying risk of progression in large
multi-center studies.
Meniscal damage
The menisci have many functions in the knee, including the equal distribu-
tion of stress between the relatively incongruous TF joint surfaces, stability
enhancement and lubrication69. The absence of a functioning meniscus in-
creases peak and average contact stresses in the medial compartment in
a range of 40e700%70e72. Early radiographic studies appear to demonstrate
that persons with a prior history of joint injury and meniscectomy are at in-
creased risk of knee OA progression35. Biswal et al.23 studied 43 subjects
and demonstrated that in the 26 subjects who had sustained meniscal tears
they had a higher average rate of progression of cartilage loss (22%) than
that seen in those who had intact menisci (14.9%) (P 0.018). Berthiaume
et al.73 investigated the relation between knee meniscus structural damage
and cartilage degradation in 32 subjects and found similar effects. We dem-
onstrated a strong association of meniscal position and meniscal damage
and cartilage loss62 with the highest quartile of medial meniscal damage hav-
ing an odds of medial progression of 6.3 (3.1e12.6). Each aspect of menis-
cal abnormality (whether change in position or damage) had a major effect
on risk of cartilage loss. To ascertain if a trial participant has meniscal dam-
age requires acquisition of an MRI during screening and having that read
with inherent concerns for both cost and participant burden prior to determin-
ing study eligibility.
BML
BML have also been found to be associated with compartment-speciﬁc
OA cartilage progression measured semi-quantitatively61,74. Medial TF com-
partment BML occurred mostly in those with varus malalignment, and lateral
TF lesions in those with valgus limbs. Of 75 knees with medial lesions, 25
(36.0%) showed medial progression vs only 12/148 knees (8.1%) without le-
sions [odds ratio (OR) for progression¼ 6.5, 95% conﬁdence interval (CI)
3.0,14.0]. 69% of knees destined to progress medially had medial lesions.
Lateral lesions conferred a similar marked risk of lateral progression. These
increased risks were attenuated by 30e50% after adjusting for limb align-
ment. This demonstrates that BMLs are a potent risk factor for predicting pro-
gression in knee OA, and their relation to progression is explained, in part, by
their association with limb alignment. Like meniscal damage, to ascertain if
a trial participant has a BML requires acquisition of an MRI during screening
and having that read with inherent concerns for both cost and participant bur-
den prior to determining study eligibility.
Stage of disease
By selecting participants with the presence of a pre-existing JSN on
X-ray12 or full thickness cartilage defects on MRI the ability to demonstrate
progression in that region is markedly improved. A recent longitudinal anal-
ysis demonstrated that by selecting persons with Kellgren and Lawrence
(K&L) Grade¼ 3 at baseline this group demonstrated the greatest change
in JSW over 12 months12. A recent MRI study demonstrates that by selecting
participants and regions with the presence of a full thickness cartilage defect
(denuded area), the ability to demonstrate change in cartilage loss in that
plate was markedly improved. Prior to stratiﬁcation, the highest SRM for
any region was 0.355, and after stratiﬁcation and selection of those with a de-
nuded area this improved to 0.62.
Whilst it is inherently appealing to identify participants at greatest risk for
progression, this methodology would include acquisition and processing of
a radiograph for JSN or MRI for denuded area during the screening process
with implications for participant burden and cost. If the central medial femur
were chosen as the region of interest only 30% of the OAI progression cohort
participants will have a focal defect in this region with implicit impact on the
screen failure rate.Trial DurationScreening
Ascertainment of
efficacy
outcome
Randomization
Symptomatic OA
As short as possible
Fig. 2. Timing of risk stratiﬁcation and characteristics of an ideal
method for risk stratiﬁcation for an idealized trial design.Muscle strength
Quadriceps weakness is common among patients with knee OA, in whom
it had been believed to be a manifestation of disuse atrophy, which develops
because of unloading of the painful extremity75. Some studies, however,
have indicated that quadriceps weakness may be present in persons with ra-
diographic changes of OA who have no history of knee pain, and in whom
lower extremity muscle mass is increased, rather than decreased76. Quadri-
ceps weakness was hence considered a risk factor for the development of
knee OA, presumably by decreasing stability of the knee joint and reducing
the shock-attenuating capacity of the muscle75,77.
The effects of strength and strength training in the setting of established
OA have been investigated; however, more work is needed to clearly estab-
lish an appropriate risk proﬁle. There is some evidence from an observationalstudy suggesting that persons with malaligned knees and greater quadriceps
strength are at greater risk for progression than those with weaker quadri-
ceps65. More research is required to tease out this relationship as the
long-term effects of strength training on knee OA progression and the mech-
anisms underlying the progression (mechanical loading, altered alignment,
altered body and fat composition) are unclear. Using muscle strength as
a risk factor for stratifying risk of progression may be more complex and
less direct than other methods, especially alignment; particularly given the
risk of muscle strength on progression may be mediated by altered
alignment.
Other risk factors or profiling indices
Synovitis is frequently present in OA and may correlate with pain and
other clinical outcomes78,79. Whilst synovitis may play a role in mediating
symptoms, its role in predisposing to further structural progression appears
controversial2,79.
Among those with established knee OA, an estimated 20e35% have an
incidental anterior cruciate ligament (ACL) tear identiﬁed by MRI80. The ef-
fect of an incidental complete ACL tear on the risk for cartilage loss appears
to be mediated by concurrent meniscal pathology81, so using this as
a method for identifying those at high risk of progression is less direct.
Compositional assessment may provide opportunities for future risk stratiﬁ-
cation. Applications of parametric mapping techniques sensitive to early
cartilage damage including T2 mapping, delayed gadolinium enhanced MRI
of cartilage (dGEMRIC) and T1rho have been extensively reviewed
elsewhere3,82. There is limited data on the longitudinal assessment of compo-
sitional measures in comparison with the aforementioned constructs83. Intui-
tively compositional measures may have a great role to play in examining
changes that occur in early disease beforegross defects areapparent, whereas
morphologic measures e both semi-quantitative and quantitative e may have
a greater role in later stages of disease. Particularly for supposedly ‘‘early’’
changes of OA, however, the natural course of these changes and the relation-
ship with clinical outcome remain to be established. dGEMRIC appears to be
helpful in determining those personswith hip dysplasiawhohave a poorer prog-
nosis andmay be helpful in ascertaining those at greatest risk of progression84.
The data available on stratifying risk of progression for knee OA using compo-
sitional measures is limited.IMPLICATIONS FOR TRIAL DESIGNIn an effort to shorten discovery and development timelines, clinical trial
brevity is paramount. This is particularly the case during phase II and III stud-
ies, where the content of this review is directly applicable. As OA is typically
a very slow progressive condition, one can optimize trial efﬁciency by ﬁnding
more responsive endpoint/s and/or stratifying the study sample to further en-
hance efﬁciency. Without stratiﬁcation the options would be to include
a larger number of subjects and/or follow them for a longer period of time,
cognizant of the fact that trials of a shorter duration typically have a lower
dropout rate (Fig. 2).
There are a number of critical decisions that need to be made in clinical
trial planning early in the design phase including the selection of the appro-
priate primary outcome. Ideally this measure should be simple (relatively
easy to perform, preferably non-invasive and widely available at a number
of centers), reliable (reproducible and standardizable across multiple
1405Osteoarthritis and Cartilage Vol. 17, No. 11centers), responsive (changes can be detected in a relatively small popula-
tion and in a relatively short period of time), and clinically relevant (changes
in marker should translate into improved, meaningful clinical outcomes).
Once the decision of an appropriate outcome is made, further measures
of stratiﬁcation, including many of the risk factors discussed before such as
alignment, meniscal lesions, etc., may enhance the responsiveness of this
outcome. Before applying one of these screening tests for detecting rapid
progression in the design of a clinical trial, one should consider the following
ideals:
1. expense of acquisition and processing of screening test,
2. minimally burdensome both to the trial participant and timeliness of
readout for trial timeline,
3. readily available at multiple centers,
4. high positive predictive value for detecting rapid progression, and
5. low screen failure rate.
The impact of a screening test to enhance responsiveness of a structural
outcome in an OA trial is seen most immediately when assessing the sample
size requirements. Projected sample size requirements depend on (1) the
expected rate of progression in participants treated with placebo, (2) the min-
imum magnitude of the drug effect, or rate of progression expected in the ac-
tive treatment arm(s), (3) the variation in progression rate that occurs
between participants, and (4) the precision of the measurement technique.
Take the following theoretical example where we vary the rate of progression
in the placebo group by selecting different SRMs. For this example I have set
the following parameters; 80% power, 1-sided a¼ 0.05, and assume the
drug causes a 50% drop in cartilage loss. If placebo treated knees have
an annual loss of cartilage with an SRM of 0.4 a 50% drop in cartilage
loss due to the active drug this would yield an SRM of 0.2 for the active
drug arm. The sample size estimate in a two arm, 1 year parallel design trial
would be 310 per arm. At present the highest SRM in the recently published
cartilage morphometry studies isw0.45,27e29. More recent unpublished anal-
yses have demonstrated that with appropriate stratiﬁcation methods one can
select a sample at greater risk of more rapid progression i.e., a higher SRM
in the range of 0.6e0.8. If we vary the placebo SRM and in this example it
were 0.6, then we would need 139 per group. If the SRM¼ 0.8, then we
would need 78 per group. If placebo SRM¼ 1, then N¼ 51. These latter
two strata comprise what may be feasible study sample requirements given
the enormous cost and expense of following larger study samples over lon-
ger study periods.Conclusions
Current data suggests that stratiﬁcation of risk is feasi-
ble to ascertain those at risk for rapid progression using
a number of different metrics including knee alignment,
meniscal damage, BML and late stage disease. Identifying
persons at greatest risk for progression has important im-
plications for clinical trial planning and can enhance study
efﬁciency. This may however impact the generalizability of
the study ﬁndings. In addition the measures of progression
we are currently using are optimal in late stages of dis-
ease, and not early disease where intervention may be
more rational.
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